Mucosal vaccine composition

A vaccine composition, mucosal technology, applied in the direction of drug combination, microorganisms, drug delivery, etc., can solve the problems of difficulty in defending itself against infection, unclear and so on

Inactive Publication Date: 2016-05-04
NITTO DENKO CORP
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Injectable vaccines have the problem of inducing an immune response (IgG antibody production) in the blood (systemic) without inducing an immune response (IgA antibody production) in the mucous membranes, although it can prevent the pathogens caused by infection. proliferates, but has difficulty defending itself from infection by pathogens due to the mucosal route
Thus, from the example of the vaccine using lipopolysaccharide (LPS) derived from Pantoea agglomerans (Pantoea agglomerans) described in this patent document 3, the oral mucosa, eye mucosa, ear mucosa, genital mucosa, throat mucosa, respiratory tract mucosa , bronchial mucosa, pulmonary mucosa, gastric mucosa, intestinal mucosa, or rectal mucosa, it is unclear whether lipopolysaccharide (LPS) derived from Pantoea agglomerans (Pantoea agglomerans) exerts an effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mucosal vaccine composition
  • Mucosal vaccine composition
  • Mucosal vaccine composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1～10、 comparative example 1～5

[0113] A solution (445 μg / mL) containing influenza vaccine antigen (B / Wisconsin / 1 / 2010, manufactured by Osaka University Institute of Microbial Diseases) (445 μg / mL), and a solution derived from Pantoea agglomerans (Pantoea agglomerans ) solution (50 mg / mL) of lipopolysaccharide (manufactured by Innate Immunology Applied Science and Technology Co., Ltd.), was added to phosphate buffer solution (manufactured by NACALAITESQUE, INC.) to prepare a 300 μL vaccine composition. For example, in Example 1, 22.5 μL of a solution containing influenza vaccine antigen was added, 20 μL of lipopolysaccharide solution derived from Pantoea agglomerans was added, and then phosphate buffer was added to make the total amount 300 μL. Other Examples and Comparative Examples were also appropriately diluted to form a content equivalent to the dose. In Comparative Example 5, only phosphate buffered saline (NACALAITESQUE, INC. .system).

[0114] Six mice (8-week-old female BALB / C mice, Japan SLC, Inc....

Embodiment 11～20、 comparative example 6～9

[0120] In addition to changing the solution containing the influenza vaccine antigen from B / Wisconsin / 1 / 2010 to A / California / 07 / 2009 (H1N1, manufactured by Osaka University Microbiological Disease Research Association) (801 μg / mL), basically by The operations of Examples 1-10 and Comparative Examples 1-5 produced vaccine compositions corresponding to Table 2. For example, in Example 11, after adding 12.5 μL of the solution containing influenza vaccine antigen and 20 μL of the lipopolysaccharide solution derived from Pantoea agglomerans (Pantoea agglomerans), phosphate buffer was added to make the total amount 300 μL.

[0121] Six mice (8-week-old female BALB / C mice, Japan SLC, Inc.) were anesthetized, and 30 μL of the prepared vaccine composition was sublingually administered to each mouse. One week after the administration, the mice were anesthetized again, and 30 μL of the prepared vaccine composition was sublingually administered to each mouse. After the second administrat...

Embodiment 21～24、 comparative example 10～12

[0125] In addition to changing the vaccine antigen from influenza to a solution containing pneumococcal capsular polysaccharide (PneumovaxNP, MSDK.K.) (1150 μg / mL), basically through the procedures based on Examples 1-10 and Comparative Examples 1-5 The procedure produced vaccine compositions corresponding to Table 3. For example, in Example 21, after adding 8.7 μL of a solution containing pneumococcal capsular polysaccharide and 2 μL of a solution of lipopolysaccharide derived from Pantoea agglomerans (Pantoea agglomerans), phosphate buffer was added to make the total amount 300 μL.

[0126] Six mice (8-week-old female BALB / C mice, Japan SLC, Inc.) were anesthetized, and 30 μL of the prepared vaccine composition was sublingually administered to each mouse. One week after the administration, the mice were anesthetized again, and 30 μL of the prepared vaccine composition was sublingually administered to each mouse. After the second administration and one week later, the serum ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The purpose of the present invention is to provide a vaccine composition which is safe and effective as a preventive medicine or a treatment medicine for infections and / or cancer, can effectively induce a systemic immune response and a mucosal immune response, and which is capable of being administered to the oral mucosa, ocular mucosa, ear mucosa, genital mucosa, pharyngeal mucosa, respiratory mucosa, bronchial mucosa, pulmonary mucosa, gastric mucosa, intestinal mucosa, or rectal mucosa. The present invention is a mucosal vaccine composition administered to at least one type of mucous membrane of a person or animal, the mucous membrane being selected from a group comprising the oral mucosa, ocular mucosa, ear mucosa, genital mucosa, pharyngeal mucosa, respiratory mucosa, bronchial mucosa, pulmonary mucosa, gastric mucosa, intestinal mucosa, and rectal mucosa. The mucosal vaccine composition is characterized by containing at least one type of antigen, and, as an immunostimulant agent, a lipopolysaccharide or a salt thereof derived from at least one type of a gram-negative bacterium selected from a group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter. Moreover, the mucosal vaccine composition is characterized in that the mass ratio of the abovementioned immunostimulant agent and antigen (the total mass of the immunostimulant agent / the total mass of the antigen) is between 0.002 and 500.

Description

technical field [0001] The present invention relates to an agent useful as a preventive or therapeutic agent for infectious diseases and cancer, and capable of treating oral mucosa, ocular mucosa, ear mucosa, genital mucosa, throat mucosa, respiratory tract mucosa, bronchial mucosa, lung mucosa, gastric mucosa, intestinal mucosa or Mucosal vaccine compositions for rectal mucosal administration. In particular, the present invention relates to a mucosal vaccine composition capable of safely and effectively inducing a systemic immune response and a mucosal immune response by administering a specific lipopolysaccharide as an adjuvant to the mucosal surface together with an antigen. Background technique [0002] As the dosage form of vaccine preparations, most of the commercialized preparations are now injections. Injectable vaccines have the problem of inducing an immune response (IgG antibody production) in the blood (systemic) without inducing an immune response (IgA antibody...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K9/06A61K9/08A61K9/12A61P37/04
CPCA61K39/00A61K2039/541A61K2039/542A61K2039/543A61K2039/544A61K2039/55572A61K39/39A61P31/00A61P31/16A61P35/00A61P37/04A61K39/0005A61K39/092A61K39/12A61K39/13A61K39/145A61K39/15A61K2039/52A61K2039/525C12N7/00C12N2710/20034C12N2720/12334C12N2760/16034C12N2770/32634
Inventor 深坂昌弘堀光彦大久保胜之浅利大介冈崎有道清远英司松下恭平
Owner NITTO DENKO CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap